Your browser is no longer supported. Please, upgrade your browser.
Arcus Biosciences, Inc.
Index- P/E- EPS (ttm)-2.80 Insider Own20.60% Shs Outstand67.08M Perf Week-0.64%
Market Cap1.77B Forward P/E- EPS next Y-3.80 Insider Trans63.10% Shs Float44.83M Perf Month-14.61%
Income-167.70M PEG- EPS next Q-0.89 Inst Own57.40% Short Float14.44% Perf Quarter-31.71%
Sales85.20M P/S20.73 EPS this Y-16.00% Inst Trans1.19% Short Ratio12.14 Perf Half Y-15.22%
Book/sh9.91 P/B2.51 EPS next Y-16.60% ROA-22.40% Target Price- Perf Year-9.75%
Cash/sh11.65 P/C2.14 EPS next 5Y- ROE-31.30% 52W Range16.69 - 42.36 Perf YTD-4.12%
Dividend- P/FCF25.38 EPS past 5Y- ROI-24.70% 52W High-41.24% Beta-
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low49.13% ATR1.27
Employees236 Current Ratio6.40 Sales Q/Q427.80% Oper. Margin- RSI (14)36.96 Volatility4.45% 4.58%
OptionableYes Debt/Eq0.00 EPS Q/Q-72.70% Profit Margin- Rel Volume0.53 Prev Close24.88
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume533.14K Price24.89
Recom1.70 SMA20-2.35% SMA50-15.55% SMA200-12.08% Volume280,159 Change0.04%
Nov-24-20Initiated Berenberg Buy $50
Nov-23-20Initiated Evercore ISI Outperform
Apr-03-20Initiated Cantor Fitzgerald Overweight $21
Mar-04-20Initiated Barclays Overweight $24
Nov-12-19Initiated SunTrust Buy $20
Sep-27-19Initiated Mizuho Buy $22
May-24-19Resumed Citigroup Buy $25
Oct-09-18Initiated Wedbush Outperform $22
Apr-09-18Initiated Leerink Partners Outperform $21
Apr-09-18Initiated Goldman Neutral $18
Apr-09-18Initiated Citigroup Buy $18
Jun-09-21 04:10PM  
May-25-21 04:10PM  
May-19-21 05:05PM  
May-11-21 04:10PM  
May-05-21 08:15PM  
May-01-21 07:31PM  
Apr-26-21 04:10PM  
Apr-10-21 08:33AM  
Apr-09-21 04:10PM  
Apr-03-21 04:10AM  
Mar-24-21 04:15PM  
Mar-12-21 12:24PM  
Mar-09-21 04:10PM  
Mar-04-21 12:13AM  
Feb-28-21 02:09AM  
Feb-25-21 04:10PM  
Feb-24-21 04:10PM  
Feb-11-21 04:10PM  
Feb-10-21 05:27AM  
Feb-09-21 04:10PM  
Feb-01-21 04:21PM  
Jan-26-21 04:10PM  
Jan-20-21 01:43PM  
Jan-15-21 08:03AM  
Jan-14-21 08:36AM  
Jan-12-21 04:10PM  
Jan-11-21 05:03PM  
Jan-06-21 04:10PM  
Jan-04-21 08:34AM  
Dec-10-20 04:10PM  
Dec-09-20 07:30PM  
Nov-18-20 04:10PM  
Nov-12-20 07:22AM  
Nov-10-20 05:30PM  
Nov-05-20 04:10PM  
Oct-29-20 06:59AM  
Oct-20-20 01:20PM  
Oct-08-20 05:00PM  
Oct-01-20 04:41PM  
Sep-28-20 02:43PM  
Sep-10-20 04:10PM  
Aug-27-20 04:10PM  
Aug-18-20 08:18AM  
Aug-17-20 12:14PM  
Aug-11-20 04:10PM  
Aug-06-20 04:10PM  
Aug-04-20 04:10PM  
Jul-28-20 04:10PM  
Jul-17-20 10:37AM  
Jul-13-20 04:05PM  
Jul-09-20 04:15PM  
Jul-07-20 04:10PM  
Jun-29-20 11:30AM  
Jun-17-20 01:54PM  
Jun-12-20 11:30AM  
Jun-09-20 04:10PM  
Jun-03-20 04:20PM  
Jun-02-20 08:33AM  
May-29-20 06:47PM  
May-28-20 10:37PM  
May-27-20 04:46PM  
May-26-20 04:10PM  
May-15-20 09:25AM  
May-12-20 06:20AM  
May-11-20 04:15PM  
May-05-20 07:25PM  
Apr-30-20 12:34PM  
Apr-17-20 11:25AM  
Apr-16-20 04:39PM  
Apr-15-20 06:36PM  
Apr-09-20 04:30PM  
Apr-03-20 09:46AM  
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jarrett JenniferChief Operating OfficerJun 04Sale24.911,04426,006119,174Jun 07 04:47 PM
KANEKO YASUNORIDirectorApr 23Buy31.374,133129,6527,133Apr 26 04:16 PM
Grossman WilliamChief Medical OfficerApr 23Sale31.374,133129,6526,717Apr 26 04:14 PM
FALBERG KATHRYN EDirectorMar 31Buy28.3520,000566,996102,106Apr 02 11:38 AM
Grossman WilliamChief Medical OfficerMar 16Sale35.032,12774,50910,850Mar 18 04:37 PM
Jarrett JenniferChief Operating OfficerMar 16Sale35.038,661303,394116,973Mar 18 04:36 PM
GILEAD SCIENCES INC10% OwnerJan 31Buy39.005,650,000220,350,00013,913,029Feb 02 04:52 PM
Grossman WilliamChief Medical OfficerDec 16Sale31.352,11766,3686,727Dec 18 04:51 PM
Goeltz II Robert C.Chief Financial OfficerSep 09Buy21.575,000107,8485,000Sep 09 04:53 PM
ROSEN TERRY JChief Executive OfficerAug 10Buy23.3832,050749,4033,231,179Aug 11 05:13 PM
ROSEN TERRY JChief Executive OfficerAug 07Buy21.4411,655249,9113,199,129Aug 11 05:13 PM
Grossman WilliamChief Medical OfficerJul 31Buy19.722003,945600Aug 04 06:13 PM